Anti-CD4 CAR T-cell therapy (University of Pennsylvania)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CD4 CAR T-cell therapy (University of Pennsylvania)

Drug Alias NameCD4 CAR+CCR5 ZFN T-cell therapy抗CD4嵌合抗原受体T细胞疗法（宾夕法尼亚大学）Genetically modified autologous T-cell therapyCD4 CAR+CCR5 ZFN modified T cell therapyCD4 CAR+C34-CXCR4+CCR5 ZFN T-cell therapy +[8]

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT-cell surface antigen CD4 modulators

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A